Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Osimertinib Approaches EU Approval in Locally Advanced EGFR+ NSCLC After Chemoradiation

November 20th 2024

Osimertinib has been recommended for approval in patients with locally advanced, unresectable, EGFR-mutant NSCLC after chemoradiation.

Lisaftoclax NDA Accepted for Review in China for Relapsed/Refractory CLL/SLL

November 20th 2024

An NDA for lisaftoclax in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma has been accepted for review.

Retrospective Data Show BTK Inhibitors May Be Optimal Second-Line Approach in Late-Relapse Mantle Cell Lymphoma

November 19th 2024

Second-line BTK inhibitors were associated with improved PFS2 and OS2 in late-relapsed mantle cell lymphoma.

Toripalimab Plus Chemo Approved in UK for Frontline Nasopharyngeal Carcinoma and ESCC

November 18th 2024

The UK MHRA approved frontline toripalimab plus chemotherapy for recurrent/metastatic NPC, as well as for advanced, recurrent, or metastatic ESCC.

Amivantamab/Lazertinib Combo Approaches EU Approval in EGFR+ Advanced NSCLC

November 18th 2024

The EMA’s CHMP has issued a positive opinion regarding the use of amivantamab plus lazertinib in select patients with EGFR+ non–small cell lung cancer.

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

November 15th 2024

The FDA has approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 year and older with relapsed or refractory acute leukemia and a KMT2A translocation.

Dr Dimopoulos on Efficacy Findings From the DREAMM-8 Trial in Multiple Myeloma

November 9th 2024

Meletios Dimopoulos, MD, discusses the design of and findings from the DREAMM-8 trial investigating BPd in patients with multiple myeloma.

Dr Singer on the Efficacy of IO/TKI Doublets in Advanced RCC

November 9th 2024

Adam E. Singer, MD, PhD, discusses currently available combination treatment regimens for the first-line treatment of patients with renal cell carcinoma.

OncLive’s October Roundup of Key FDA Approvals in Oncology

November 5th 2024

Here is your snapshot of all therapeutic options that the FDA approved in October 2024 spanning tumor types.

Regorafenib Provides Modest Survival Benefit in Refractory Advanced Gastric/GEJ Cancer

November 4th 2024

Regorafenib improved overall survival vs placebo in refractory advanced gastric or gastroesophageal junction cancer.

SHR-A1921 Demonstrates Early Efficacy in Platinum-Resistant Ovarian Cancer

November 3rd 2024

SHR-A1921 showcased early efficacy with a manageable safety profile in patients with platinum-resistant ovarian cancer.

Casdatifan Demonstrates Durable Activity in Metastatic Clear Cell Renal Cell Carcinoma

November 1st 2024

Casdatifan was well tolerated and had durable clinical activity in patients with metastatic clear cell renal cell carcinoma.

FDA Grants Regenerative Medicine Advanced Therapy Designation to ALLO-316 in CD70+ Advanced RCC

October 31st 2024

The FDA has granted regenerative medicine advanced therapy to ALLO-316 in CD70-positive advanced or metastatic renal cell carcinoma.

FDA Delays PDUFA Date for Sotorasib Plus Panitumumab in KRAS G12C+ mCRC

October 30th 2024

The FDA has extended the PDUFA date for sotorasib plus panitumumab application in KRAS G12C+ metastatic colorectal cancer.

Precision Medicine Unfolds in Oncology, Bearing Substantial Implications for the Future

October 30th 2024

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the inner workings of oncology: https://rb.gy/bvumdn.

BGB-16673 Shows Early Activity, Tolerability in Heavily Pretreated Waldenström Macroglobulinemia

October 29th 2024

BGB-16673 had acceptable tolerability and showcased early antitumor activity in patients with relapsed/refractory Waldenström macroglobulinemia.

Empowering Community Cancer Care: Importance of Outreach Initiatives

October 23rd 2024

In this episode of OncChats: Empowering Community Cancer Care, Dr. Rai emphasizes the importance of community outreach and support for patients with cancer.

Empowering Community Cancer Care: Survivorship and Support Programs

October 23rd 2024

In this episode of OncChats: Empowering Community Cancer Care, Dr Woodworth sheds light on the “Road to Recovery” survivorship program at Henry Mayo, which supports cancer survivors by providing them with fitness, education, and mental health resources.

Empowering Community Cancer Care: Integrating Screening Programs

October 23rd 2024

In this episode of OncChats: Empowering Community Cancer Care, experts discuss their collaborative approach to cancer screening, emphasizing the importance of community efforts and individual assessments in integrating genetic testing and screenings into routine practice.

Empowering Community Cancer Care: Promoting Education

October 23rd 2024

In this episode of OncChats: Empowering Community Cancer Care, Dr Woodworth discusses her outreach efforts in the Santa Clarita community, including partnering with organizations like the American Cancer Society, hosting educational panels for women, and providing continuing medical education for local physicians to ensure comprehensive cancer care and awareness.